Tessio Rebello
Plus aucun poste en cours
Profil
Tessio Rebello is Vice President of Clinical Affairs for VIRxSYS Corp.
Prior to joining VIRxSYS, he served as Director of Clinical Development for United Therapeutics Corp.
and as Head of the Cardiovascular Division for Sigma-Tau Pharmaceuticals, Inc. Dr. Rebello received a Bachelor of Science degree from the University of Liverpool and a PhD from the University of London.
Anciens postes connus de Tessio Rebello
| Sociétés | Poste | Fin |
|---|---|---|
VIRxSYS Corp.
 VIRxSYS Corp. BiotechnologyHealth Technology VIRxSYS Corp. is a holding company, which uses its proprietary platform technologies to develop therapies for serious human diseases. Its platform technologies include lentiviral vectors as a delivery vehicle for genes against certain diseases and for vaccine therapies. Its therapies are in various stages of development from pre-clinical through Phase II clinical trials. The company was founded by Boro Dropulic, William J. Turner, and Wiliam N. Sick Jr in 1998 and is headquartered in Gaithersburg, MD. | Directeur Technique/Scientifique/R&D | 05/05/2014 |
Leadiant Biosciences, Inc.
 Leadiant Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Leadiant Biosciences, Inc. operates as a research-based pharmaceutical company. It develops and commercializes medicines for rare diseases. The company was founded in 1989 by Claudio Cavazza and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | - |
| UNITED THERAPEUTICS CORPORATION | President | 22/05/2009 |
Formation de Tessio Rebello
| The University of Liverpool | Undergraduate Degree |
| University of London | Doctorate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| UNITED THERAPEUTICS CORPORATION | Health Technology |
| Entreprise privées | 2 |
|---|---|
VIRxSYS Corp.
VIRxSYS Corp. BiotechnologyHealth Technology VIRxSYS Corp. is a holding company, which uses its proprietary platform technologies to develop therapies for serious human diseases. Its platform technologies include lentiviral vectors as a delivery vehicle for genes against certain diseases and for vaccine therapies. Its therapies are in various stages of development from pre-clinical through Phase II clinical trials. The company was founded by Boro Dropulic, William J. Turner, and Wiliam N. Sick Jr in 1998 and is headquartered in Gaithersburg, MD. | Health Technology |
Leadiant Biosciences, Inc.
Leadiant Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Leadiant Biosciences, Inc. operates as a research-based pharmaceutical company. It develops and commercializes medicines for rare diseases. The company was founded in 1989 by Claudio Cavazza and is headquartered in Gaithersburg, MD. | Health Technology |
